Skip to main content
Clinical Trials/NCT02218996
NCT02218996
Active, Not Recruiting
N/A

Treatment of Anxiety Disorders for Children and Adolescents in Regular Outpatient Clinics (TADCAROC)

Helse Stavanger HF1 site in 1 country260 target enrollmentAugust 2014

Overview

Phase
N/A
Intervention
Not specified
Conditions
Anxiety Disorders
Sponsor
Helse Stavanger HF
Enrollment
260
Locations
1
Primary Endpoint
The Anxiety Disorder Interview Schedule for Diagnostic and Statistical Manual (DSM-IV), child and parent versions (ADIS- C/P; Silverman & Albano, 1996).
Status
Active, Not Recruiting
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to examine the content of the treatment being delivered for anxiety disorders for children and adolescents in the regular outpatient clinics in western Norway. The study will also collect data before and after treatment to evaluate the result of the treatment. Furthermore, as part of the study we aim to collect normative data on two questionnaires used to identify anxiety symptoms and the extent to which anxiety interfere with daily functioning. We also aim to develop a quality indicator for anxiety treatment that can be used to monitor treatment in the regular outpatient service, based on the results of the current study.

Registry
clinicaltrials.gov
Start Date
August 2014
End Date
December 31, 2029
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of an anxiety disorder (including PTSD and OCD) based on the diagnostic interview ADIS (ADIS-C/P; Silverman \& Albano, 1996).
  • The anxiety disorder is the patients primary diagnosis.
  • Informed concent is given.

Exclusion Criteria

  • The patient is in need for other primary treatment intervention (e.g., psychosis, suicidality risk)

Outcomes

Primary Outcomes

The Anxiety Disorder Interview Schedule for Diagnostic and Statistical Manual (DSM-IV), child and parent versions (ADIS- C/P; Silverman & Albano, 1996).

Time Frame: The primary outcome measure will be administered pre-treatment, post treatment (an expected average of 20 weeks) and at ten year follow-up.

Diagnostic interview for anxiety disorders and other comorbid disorders. For the 10-year follow-up we anticipate to use another version of the diagnostic interview schedule based on revised diagnostic criteria for anxiety disorders.

Secondary Outcomes

  • Children's Anxiety Life Interference Scale (CALIS; Lyneham et al., 2013)(This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks).)
  • Spence Children's Anxiety Scale (SCAS; Spence, 1998)(This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks).)
  • Short Mood & Feeling Questionaire (SMFQ; Angold et al., 1995).(This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks))
  • The Screen for Child Anxiety Related Emotional Disorders (SCARED; Birmaher et al., 1999).(This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks).)
  • The Strengths and Difficulties Questionnaire (SDQ; Goodman, 1997)(This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks))
  • Clinical Global Impressions (CGI; Guy, 1976).(The outcome measure will be administered pre-treatment, post treatment (an expected average of 20 weeks) and at ten year follow-up.)

Study Sites (1)

Loading locations...

Similar Trials